Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Synairgen
Biotech
NIH puts a lid on Synairgen's ACTIV-2 arm amid omicron spread
The NIH kiboshed Synairgen’s ACTIV-2 arm testing the company's drug in in nonhospitalized patients due to a “significant shift” in the pandemic.
Max Bayer
Mar 17, 2022 11:20am
Synairgen ACTIV-2 trial paused while NIH tweaks study design
Mar 3, 2022 3:30pm
Synairgen's COVID-19 SPRINTER trial falls at final hurdle
Feb 22, 2022 7:05am
Inhaled interferon doesn’t enhance COVID-19 entry point: study
Jan 11, 2021 11:00am
Synairgen stock climbs on COVID-19 treatment results
Nov 13, 2020 10:38am
Synairgen shares soar on COVID-19 treatment, but caveats abound
Jul 20, 2020 4:53am
